[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG10201913990RA - PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF - Google Patents

PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Info

Publication number
SG10201913990RA
SG10201913990RA SG10201913990RA SG10201913990RA SG10201913990RA SG 10201913990R A SG10201913990R A SG 10201913990RA SG 10201913990R A SG10201913990R A SG 10201913990RA SG 10201913990R A SG10201913990R A SG 10201913990RA SG 10201913990R A SG10201913990R A SG 10201913990RA
Authority
SG
Singapore
Prior art keywords
pyrazin
pyrrolo
imidazo
trifluoroethyl
carboxamide
Prior art date
Application number
SG10201913990RA
Inventor
Ayman D Allian
Jayanthy Jayanth
Mohamed-Eslam F Mohamed
Mathew M Mulhern
Fredrik Lars Nordstrom
Ahmed A Othman
Michael J Rozema
Lakshmi Bhagavatula
Patrick J Marroum
Peter T Mayer
Ahmad Y Sheikh
Thomas B Borchardt
KLÜNDER Ben
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57209916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201913990R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG10201913990RA publication Critical patent/SG10201913990RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SG10201913990RA 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF SG10201913990RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562242797P 2015-10-16 2015-10-16
US201562267672P 2015-12-15 2015-12-15
US201662301537P 2016-02-29 2016-02-29
US201662352380P 2016-06-20 2016-06-20

Publications (1)

Publication Number Publication Date
SG10201913990RA true SG10201913990RA (en) 2020-03-30

Family

ID=57209916

Family Applications (8)

Application Number Title Priority Date Filing Date
SG10201913999PA SG10201913999PA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913989QA SG10201913989QA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913990RA SG10201913990RA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913997WA SG10201913997WA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913993QA SG10201913993QA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913986YA SG10201913986YA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913987UA SG10201913987UA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG11201802990RA SG11201802990RA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201913999PA SG10201913999PA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913989QA SG10201913989QA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Family Applications After (5)

Application Number Title Priority Date Filing Date
SG10201913997WA SG10201913997WA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913993QA SG10201913993QA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913986YA SG10201913986YA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913987UA SG10201913987UA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG11201802990RA SG11201802990RA (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Country Status (14)

Country Link
US (37) US20170129902A1 (en)
EP (2) EP3362455A1 (en)
JP (5) JP6770775B2 (en)
KR (1) KR20180081523A (en)
CN (4) CN116270646A (en)
AU (3) AU2016340167B2 (en)
BR (1) BR122022024925B1 (en)
CA (2) CA3123260A1 (en)
HK (1) HK1263380A1 (en)
IL (3) IL314468A (en)
MX (2) MX2018004605A (en)
RU (1) RU2018117889A (en)
SG (8) SG10201913999PA (en)
WO (1) WO2017066775A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2836833A1 (en) 1978-08-23 1980-04-10 Volkswagenwerk Ag INTERNAL COMBUSTION ENGINE WITH CYLINDERS IN TWO ROWS
EP3950692A1 (en) 2009-12-01 2022-02-09 AbbVie Inc. Novel tricyclic compounds
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN116270646A (en) 2015-10-16 2023-06-23 艾伯维公司 Process for preparing imidazo [1,2-a ] pyrrolo [2,3-e ] pyrazines and solid forms thereof
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
JP2020510016A (en) 2017-03-09 2020-04-02 アッヴィ・インコーポレイテッド Methods for treating Crohn's disease and ulcerative colitis
WO2019016745A1 (en) * 2017-07-19 2019-01-24 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of pyrrolidine derivatives
BR112020019814A2 (en) * 2018-03-30 2021-01-05 Incyte Corporation TREATMENT OF SUPURATIVE HYDRADENITIS USING JAK INHIBITORS
CN110872250B (en) * 2018-08-31 2023-01-10 苏州鹏旭医药科技有限公司 Two compounds, preparation methods thereof and application thereof in synthesis of ursitinib
WO2020043033A2 (en) 2018-08-31 2020-03-05 苏州鹏旭医药科技有限公司 Synthesis methods for upadacitinib and intermediate thereof
US20220002306A1 (en) * 2018-09-29 2022-01-06 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of upadacitinib and preparation method and use thereof
CN111217819B (en) * 2018-11-27 2021-05-14 杭州科巢生物科技有限公司 Synthetic method of sepiatinib
EP3891151A1 (en) 2018-12-05 2021-10-13 LEK Pharmaceuticals d.d. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
CN109369659B (en) * 2018-12-06 2020-10-27 浙江师范大学 Synthetic method of JAK inhibitor
WO2020115213A1 (en) 2018-12-07 2020-06-11 Lek Pharmaceuticals D.D. Solvate of a selective jak1 inhibitor
CN109705011B (en) * 2019-01-18 2021-02-19 浙江师范大学 Synthetic method of Upacatinib intermediate and intermediate
WO2020177645A1 (en) * 2019-03-01 2020-09-10 苏州科睿思制药有限公司 Upadacitinib crystal form and preparation method therefor and use thereof
WO2020202183A1 (en) 2019-03-29 2020-10-08 Mylan Laboratories Limited The process for the preparation of upadacitinib and its intermediates
CN111909160B (en) 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 Martinib salt compound and preparation method thereof
CN110229160A (en) * 2019-06-11 2019-09-13 南京新酶合医药科技有限公司 The preparation method of (5- tosyl -5H- pyrrolo- [2,3-b] pyrazine -2- base) urethanes
CN110117245B (en) * 2019-06-21 2021-03-02 浙江师范大学 Synthetic method of JAK inhibitor intermediate
WO2021005484A1 (en) * 2019-07-11 2021-01-14 Mankind Pharma Ltd. Pyrrolidine compounds, its salt and use in the preparation of upadacitinib thereof
CN110615753A (en) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 Synthesis method of (3R,4S) -1-substituted-4-ethylpyrrole-3-carboxylic acid
AU2020359635A1 (en) * 2019-09-30 2022-04-21 Abbvie Inc. Treating spondyloarthritic and psoriatic conditions with upadacitinib
CN111072543B (en) * 2019-11-13 2021-06-04 北京海美桐医药科技有限公司 Preparation method and application of (3R,4S) -4-ethylpyrrolidine-3-carboxylic acid compound
JP2023510111A (en) * 2019-12-19 2023-03-13 クリア、スペイン、エセ、ア、ウ Methods and intermediates for the preparation of upadacitinib
WO2021176473A1 (en) * 2020-03-05 2021-09-10 Mylan Laboratories Limited A process for the preparation of upadacitinib and its intermediates
CN114206877B (en) * 2020-06-05 2024-04-19 苏州科睿思制药有限公司 Crystal form of Martinib and preparation method and application thereof
WO2022007629A1 (en) 2020-07-08 2022-01-13 苏州科睿思制药有限公司 Crystal form of upadacitinib, preparation method therefor, and use thereof
WO2022044037A1 (en) 2020-08-24 2022-03-03 Mylan Laboratories Limited An improved process for the preparation of upadacitinib intermediate
CA3216378A1 (en) * 2021-04-07 2022-10-13 Abbvie Inc. Cocrystals of upadacitinib
CN115724781A (en) * 2021-08-30 2023-03-03 凯特立斯（深圳）科技有限公司 Method for synthesizing empatinib key chiral intermediate
CN114380837B (en) * 2021-12-27 2023-06-30 上海邈金医药科技有限公司 Compound with Janus kinase inhibition activity, composition comprising compound and application of compound
WO2023131978A1 (en) * 2022-01-06 2023-07-13 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of upadacitinib
AU2022435654A1 (en) 2022-01-20 2024-08-01 Renata Pharmaceutical (Ireland) Limited Sustained release pharmaceutical composition of upadacitinib
CN114315679B (en) * 2022-01-21 2024-08-30 杭州新博思生物医药有限公司 Martinib chiral preparation method of intermediate
EP4215196A1 (en) 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
WO2024075131A1 (en) * 2022-10-03 2024-04-11 Natco Pharma Limited Co-crystal of upadacitinib and diacetyl-d-tartaric acid and process for the preparation thereof
WO2024197127A1 (en) 2023-03-22 2024-09-26 Abbvie Inc. Methods of treating pediatric patients with upadacitinib
CN117285537B (en) * 2023-11-27 2024-02-06 中节能万润股份有限公司 Preparation method of Marpatinib
CN117285536B (en) * 2023-11-27 2024-02-20 中节能万润股份有限公司 Preparation method of Martinib intermediate
CN117285535B (en) * 2023-11-27 2024-02-02 中节能万润股份有限公司 Preparation method of Marpatinib intermediate and salified intermediate
CN117447481A (en) * 2023-12-23 2024-01-26 潍坊医学院 Amorphous substance of Martinib-pyroglutamate and preparation method and application thereof
CN118047785A (en) * 2024-03-07 2024-05-17 和鼎（南京）医药技术有限公司 Method for preparing Wu Pati Ni and intermediate thereof
CN118370734B (en) * 2024-06-26 2024-10-01 山东则正医药技术有限公司 Martinib sustained release tablet and preparation method thereof

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB716327A (en) 1951-09-05 1954-10-06 Ici Ltd New heterocyclic compounds
BE640616A (en) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US3663559A (en) 1969-12-03 1972-05-16 Union Carbide Corp Preparation of oxo-furo-pyridines from furylvinyl isocyanates
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4053474A (en) 1976-04-21 1977-10-11 E. R. Squibb & Sons, Inc. Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
DE69033614T2 (en) 1989-10-20 2001-04-19 Kyowa Hakko Kogyo K.K., Tokio/Tokyo Condensed purine derivatives
CA2073500C (en) 1990-01-11 2008-03-25 Phillip Dan Cook Compositions and methods for detecting and modulating rna activity and gene expression
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
DE10199067I2 (en) 1991-03-18 2006-03-16 Univ New York Human Tumor Necrosis Factor Specific Monoclonal and Chimeric Antibodies
WO1992022552A1 (en) 1991-06-14 1992-12-23 The Upjohn Company IMIDAZO[1,5-a]QUINOXALINES
US5212310A (en) 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5266698A (en) 1992-04-30 1993-11-30 Neurogen Corporation Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
US5306819A (en) 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
EP0669836B1 (en) 1992-11-13 1996-07-03 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
TW270118B (en) 1993-02-26 1996-02-11 Schering Corp
US5736540A (en) 1993-07-29 1998-04-07 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5733905A (en) 1993-07-29 1998-03-31 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
RU2158127C2 (en) 1994-12-23 2000-10-27 Варнер-Ламберт Компани Method for inhibiting epidermal growth factor receptor thyrosinekinase, nitrogen-containing tricyclic compounds and pharmaceutical composition for introducing epidermal growth factor receptor thyrosinekinase inhibitor like erb- b2, erb-b3 or erb-b4 and contraceptive composition
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5521173A (en) 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
US5763137A (en) 1995-08-04 1998-06-09 Agfa-Gevaert, N.V. Method for making a lithographic printing plate
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
FR2742676B1 (en) 1995-12-21 1998-02-06 Oreal TRANSPARENT NANOEMULSION BASED ON SILICON SURFACTANTS AND USE IN COSMETICS OR DERMOPHARMACY
US5703244A (en) 1996-11-21 1997-12-30 Abbott Laboratories Process for preparation of chiral 3-amino-pyrrolidine and analogous bicyclic compounds
AU738545C (en) 1997-02-05 2004-06-17 Merck Sharp & Dohme Corp. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
EP1066286B1 (en) 1998-03-04 2009-04-29 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
KR20010075064A (en) 1998-09-14 2001-08-09 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Branched alkyl pyrrolidine-3-carboxylic acids
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
DE19853665B4 (en) 1998-11-20 2005-06-30 Siemens Ag Vehicle communication system and method for exchanging data in a motor vehicle
CO5271670A1 (en) 1999-10-29 2003-04-30 Pfizer Prod Inc ANTIGONISTS OF THE CORTICITROPINE RELEASE FACTOR AND RELATED COMPOSITIONS
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
CN1468241A (en) 2000-08-07 2004-01-14 Heterocyclic compounds as ligands of the gabaa receptor
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
JP2005529850A (en) 2002-02-19 2005-10-06 ファルマシア・イタリア・エス・ピー・エー Tricyclic pyrazole derivatives, their preparation and their use as antitumor agents
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
JP2006505552A (en) 2002-10-09 2006-02-16 サイオス インク． Azaindole derivatives as p38 kinase inhibitors
CA2512646A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
AR044510A1 (en) 2003-04-14 2005-09-14 Merck & Co Inc PROCEDURE AND INTERMEDIATES TO PREPARE CARBOXILIC ACIDS OF PIRROLIDINE
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
ATE419242T1 (en) 2003-10-09 2009-01-15 Abbott Lab PYRROLIDINYLUREA DERIVATIVES AS ANGIOGENESIS INHIBITORS
EP1753428A4 (en) 2004-05-14 2010-09-15 Abbott Lab Kinase inhibitors as therapeutic agents
AR049300A1 (en) 2004-06-15 2006-07-12 Schering Corp MGLUR1 ANTAGONIST TRICICLIC COMPOUNDS AS THERAPEUTIC AGENTS
CN1968684A (en) 2004-06-17 2007-05-23 森林实验室公司 Modified release formulation of memantine
ATE455777T1 (en) 2004-07-23 2010-02-15 Medicines Co Leipzig Gmbh SUBSTITUTED PYRIDOÄ3',2':4,5ÜTHIENOÄ3,2-DÜPYRIMIDINES AND PYRIDOÄ3',2':4,5ÜFUROÄ3,2-DÜ-PYRIMIDINES FOR USE AS INHIBITORS OF PDA-4 AND/OR TNF-ALPHA RELEASE
EP2239262A3 (en) 2004-07-27 2011-10-19 SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CN100381175C (en) 2004-10-09 2008-04-16 山西中医学院 Microemulsion formulation and its preparation process
EP1814883A1 (en) 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
NZ555981A (en) 2004-12-21 2011-01-28 Arena Pharm Inc Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
WO2006074984A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
AU2006205851A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
US20060183758A1 (en) 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
EP1863813A2 (en) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
CN102127078A (en) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Heterocyclic janus kinase 3 inhibitors
US8163767B2 (en) 2005-07-14 2012-04-24 Astellas Pharma Inc. Heterocyclic Janus Kinase 3 inhibitors
CN101291938A (en) 2005-08-16 2008-10-22 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
JP4551962B2 (en) 2005-09-23 2010-09-29 コーリー ファーマシューティカル グループ，インコーポレイテッド Process for 1H-imidazo [4,5-c] pyridine and analogs thereof
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
JP2009509964A (en) * 2005-09-23 2009-03-12 メモリー・ファーマシューティカルズ・コーポレイション Indazoles, benzothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and their production and use
ES2390135T3 (en) 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Tricyclic compounds useful as kinase inhibitors
EP1973917B1 (en) 2005-12-29 2015-06-10 AbbVie Inc. Protein kinase inhibitors
ES2335710T3 (en) 2006-04-03 2010-03-31 F. Hoffmann-La Roche Ag PROCESS TO PREPARE BETA-ARIL OR HETEROARIL CARBOXI-LICOS CYCLES ENANTIOMERICALLY ENRIQUECIDOS.
WO2007143434A2 (en) 2006-05-31 2007-12-13 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents
AR062320A1 (en) 2006-08-14 2008-10-29 Boehringer Ingelheim Int FLIBANSERIN FORMULATIONS AND METHOD TO MANUFACTURE THEM
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
MX2009003650A (en) 2006-10-06 2009-04-22 Abbott Lab Novel imidazothiazoles and imidazoxazoles.
CN101679408B (en) 2006-12-22 2016-04-27 Astex治疗学有限公司 As the bicyclic heterocycles of FGFR inhibitor
CN101578285A (en) 2007-01-12 2009-11-11 安斯泰来制药株式会社 Condensed pyridine compound
CN101230059B (en) * 2007-01-23 2011-08-17 上海恒瑞医药有限公司 Bicycle aza alkyl derivative, preparation method and use in medicine thereof
US20100190787A1 (en) 2007-01-30 2010-07-29 Srinivas Rao Kasibhatla Modulators of Mitotic Kinases
WO2008112695A2 (en) 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
US7834024B2 (en) 2007-03-26 2010-11-16 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
RU2009140319A (en) 2007-04-02 2011-05-10 Палау Фарма С.А. (Es) Pyrrolpyrimidine derivatives
KR101443943B1 (en) 2007-05-07 2014-10-07 에보니크 룀 게엠베하 Solid dosage forms comprising an enteric coating with accelerated drug release
KR101222330B1 (en) 2007-05-11 2013-01-15 화이자 인코포레이티드 Amino-heterocyclic compounds
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
WO2009085310A1 (en) 2007-12-26 2009-07-09 Teva Pharmaceutical Industries Ltd. Extended-release pharmaceutical compositions containing zolpidem
EP2250172B1 (en) 2008-02-25 2011-08-31 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
ATE517107T1 (en) 2008-02-25 2011-08-15 Hoffmann La Roche PYRROLOPYRAZINE KINASE INHIBITORS
RU2503676C2 (en) 2008-02-25 2014-01-10 Ф.Хоффманн-Ля Рош Аг Pyrrolopyrazine kinase inhibitors
WO2009108827A1 (en) 2008-02-29 2009-09-03 Wyeth Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
CA2716642C (en) 2008-03-28 2017-02-28 Boehringer Ingelheim International Gmbh Method for manufacturing acid pellets
SI2299821T1 (en) 2008-06-10 2016-03-31 Abbvie Inc. Tricyclic compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
AU2009266806A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. CDK modulators
CN101638423B (en) * 2008-07-29 2012-09-05 常州高新技术产业开发区三维工业技术研究所有限公司 Phloridzin derivative as well as preparation method and application thereof
BRPI1008906B1 (en) 2009-02-24 2019-10-15 Merck Sharp & Dohme Corp. COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
WO2010117796A2 (en) 2009-03-30 2010-10-14 Codexis, Inc. Processes for the preparation of alpha-chloroketones from carboxylic acids
RU2011146059A (en) 2009-04-14 2013-05-20 Астеллас Фарма Инк. Condensed Pyrrolopyridine Derivative
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US8367689B2 (en) 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
CN101904814A (en) 2009-06-04 2010-12-08 上海恒瑞医药有限公司 Preparation method of drug loaded emulsion
FR2947276B1 (en) 2009-06-24 2012-10-26 Seppic Sa COSMETIC COMPOSITION BASED ON ION EXCHANGE RESINS LOADED WITH LIPOAMINOACIDES
US8361962B2 (en) 2009-07-27 2013-01-29 Roche Palo Alto Llc Tricyclic inhibitors of JAK
AU2010277207B2 (en) 2009-07-31 2014-06-26 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
EP2506713A4 (en) 2009-12-01 2014-09-03 Abbvie Inc Novel tricyclic compounds
EP3950692A1 (en) 2009-12-01 2022-02-09 AbbVie Inc. Novel tricyclic compounds
EA030376B1 (en) 2010-03-10 2018-07-31 Инсайт Холдингс Корпорейшн Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CA2788526A1 (en) 2010-05-14 2011-11-17 Alembic Limited Extended release formulations of desvenlafaxine base
EP2580209A4 (en) 2010-06-09 2013-11-06 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a protein
US8637529B2 (en) 2010-06-11 2014-01-28 AbbYie Inc. Pyrazolo[3,4-d]pyrimidine compounds
WO2012041814A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
US20120231083A1 (en) 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
WO2012149280A2 (en) 2011-04-29 2012-11-01 Abbott Laboratories Novel tricyclic compounds
US20130072470A1 (en) * 2011-09-21 2013-03-21 Abbvie Inc. Novel tricyclic compounds
FR2991171B1 (en) 2012-06-01 2014-05-23 Galderma Res & Dev PROCESS FOR THE PREPARATION OF A DERMATOLOGICAL COMPOSITION COMPRISING OLEOSOMES
WO2014004863A2 (en) 2012-06-27 2014-01-03 Alzheimer's Institute Of America, Inc. Compounds, compositions, and therapeutic uses thereof
AU2013292547B2 (en) 2012-07-20 2017-05-04 Zoetis Services Llc Dosing regimen for Janus Kinase (JAK) inhibitors
US20160002223A1 (en) 2013-02-21 2016-01-07 Pfizer Inc. Solid forms of a selective cdk4/6 inhibitor
BR112015019634B1 (en) 2013-02-22 2022-09-20 Pfizer Inc PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS JANUS KINASE (JAK) INHIBITORS, THEIR USE AND PHARMACEUTICAL OR VETERINARY COMPOSITION INCLUDING THEM
CN105209469A (en) 2013-03-15 2015-12-30 全球血液疗法股份有限公司 Compounds and uses thereof for the modulation of hemoglobin
JP6041823B2 (en) 2013-03-16 2016-12-14 ファイザー・インク Tofacitinib oral sustained release dosage form
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib
AU2014339897A1 (en) 2013-10-24 2016-04-21 Abbvie Inc. JAK1 selective inhibitor and uses thereof
US20170266289A1 (en) 2014-08-27 2017-09-21 Abbvie Inc. Topical formulation
EP3307246A1 (en) 2015-06-09 2018-04-18 Capsugel Belgium NV Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US20180230127A1 (en) 2015-08-13 2018-08-16 Pfizer Inc. Bicyclic-Fused Heteroaryl Or Aryl Compounds
KR102029124B1 (en) 2015-08-27 2019-10-07 화이자 인코포레이티드 Bicyclic-Fused Heteroaryl or Aryl Compounds as IRAK4 Modulators
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN116270646A (en) 2015-10-16 2023-06-23 艾伯维公司 Process for preparing imidazo [1,2-a ] pyrrolo [2,3-e ] pyrazines and solid forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
ES2858311T3 (en) 2015-11-30 2021-09-30 Anacor Pharmaceuticals Inc Topical pharmaceutical formulations for the treatment of conditions related to inflammation
WO2017126488A1 (en) 2016-01-18 2017-07-27 持田製薬株式会社 Psoriasis treatment composition and treatment method
JP7096592B2 (en) 2016-02-16 2022-07-06 ワシントン・ユニバーシティ JAK inhibitors and their use
KR102413459B1 (en) 2016-07-06 2022-06-24 듀렉트 코퍼레이션 Oral dosage form having drug composition, barrier layer and drug layer
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
JP2020510016A (en) 2017-03-09 2020-04-02 アッヴィ・インコーポレイテッド Methods for treating Crohn's disease and ulcerative colitis
MX2024008557A (en) 2022-01-13 2024-09-11 Abbvie Inc Method of administering upadacitinib to avoid adverse drug interactions and effects.

Also Published As

Publication number Publication date
US20190023714A1 (en) 2019-01-24
JP6770775B2 (en) 2020-10-21
IL283531A (en) 2021-07-29
US20230183257A1 (en) 2023-06-15
CN108368121B (en) 2023-01-13
US11198697B1 (en) 2021-12-14
US11795175B2 (en) 2023-10-24
US11680069B2 (en) 2023-06-20
MX2018004605A (en) 2018-11-29
US9879018B2 (en) 2018-01-30
US20210309667A1 (en) 2021-10-07
US20180162865A1 (en) 2018-06-14
US20230203049A1 (en) 2023-06-29
US10981923B2 (en) 2021-04-20
US20170362247A1 (en) 2017-12-21
US10597400B2 (en) 2020-03-24
US20200361949A1 (en) 2020-11-19
SG11201802990RA (en) 2018-05-30
US12077545B2 (en) 2024-09-03
US20180186805A1 (en) 2018-07-05
US10344036B2 (en) 2019-07-09
US20230058001A1 (en) 2023-02-23
US20230348481A1 (en) 2023-11-02
US11773105B2 (en) 2023-10-03
US20180222914A1 (en) 2018-08-09
JP2022107001A (en) 2022-07-20
US12116373B2 (en) 2024-10-15
JP7358317B2 (en) 2023-10-10
US20230374027A1 (en) 2023-11-23
US11780847B1 (en) 2023-10-10
US12091415B2 (en) 2024-09-17
US20240034740A1 (en) 2024-02-01
US20180141955A1 (en) 2018-05-24
US20190322677A1 (en) 2019-10-24
SG10201913987UA (en) 2020-03-30
US20170342083A1 (en) 2017-11-30
CA3123260A1 (en) 2017-04-20
US20240174682A1 (en) 2024-05-30
US12110298B2 (en) 2024-10-08
WO2017066775A1 (en) 2017-04-20
SG10201913986YA (en) 2020-03-30
AU2016340167A1 (en) 2018-04-26
US11535624B2 (en) 2022-12-27
US12134621B2 (en) 2024-11-05
US20240010656A1 (en) 2024-01-11
US20220298165A1 (en) 2022-09-22
US20210363149A1 (en) 2021-11-25
US11787815B1 (en) 2023-10-17
US9879019B2 (en) 2018-01-30
US20200317682A1 (en) 2020-10-08
AU2021236570B2 (en) 2023-11-02
US20230322794A1 (en) 2023-10-12
AU2016340167A8 (en) 2018-05-10
SG10201913997WA (en) 2020-03-30
JP2023113917A (en) 2023-08-16
US10017517B2 (en) 2018-07-10
IL258654A (en) 2018-06-28
EP4219503A1 (en) 2023-08-02
US12110297B2 (en) 2024-10-08
US10202394B2 (en) 2019-02-12
JP2021020902A (en) 2021-02-18
US20230219968A1 (en) 2023-07-13
US10519164B2 (en) 2019-12-31
CN108368121A (en) 2018-08-03
US9963459B1 (en) 2018-05-08
CN116270646A (en) 2023-06-23
SG10201913999PA (en) 2020-03-30
US20180057502A1 (en) 2018-03-01
AU2021236570A1 (en) 2021-10-28
JP2024073591A (en) 2024-05-29
US11718627B2 (en) 2023-08-08
RU2018117889A3 (en) 2020-08-12
KR20180081523A (en) 2018-07-16
US12103933B2 (en) 2024-10-01
US20190315761A1 (en) 2019-10-17
US20230312593A1 (en) 2023-10-05
US10730883B2 (en) 2020-08-04
IL314468A (en) 2024-09-01
US11661425B2 (en) 2023-05-30
CN116284011A (en) 2023-06-23
SG10201913993QA (en) 2020-03-30
BR122022024925B1 (en) 2023-11-28
US20170129902A1 (en) 2017-05-11
US10202393B2 (en) 2019-02-12
RU2018117889A (en) 2019-11-20
AU2023251492A1 (en) 2023-11-09
US20180222913A1 (en) 2018-08-09
US20230057084A1 (en) 2023-02-23
US20200291040A1 (en) 2020-09-17
SG10201913989QA (en) 2020-03-30
CA3002220A1 (en) 2017-04-20
US20240166657A1 (en) 2024-05-23
CN116270645A (en) 2023-06-23
CA3002220C (en) 2021-07-20
US20200181158A1 (en) 2020-06-11
US9951080B2 (en) 2018-04-24
US20230331735A1 (en) 2023-10-19
AU2016340167B2 (en) 2021-06-24
EP3362455A1 (en) 2018-08-22
HK1263380A1 (en) 2020-05-29
MX2021013812A (en) 2021-12-14
US11186584B2 (en) 2021-11-30
JP2019501865A (en) 2019-01-24
US20240317770A1 (en) 2024-09-26
US20230312595A1 (en) 2023-10-05
US10981924B2 (en) 2021-04-20
US20230303582A1 (en) 2023-09-28
BR112018007677A2 (en) 2018-11-06

Similar Documents

Publication Publication Date Title
IL283531A (en) Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
IL268737A (en) Processes for the preparation of benzodiazepine derivatives
IL266170A (en) Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof
EP3468973A4 (en) Solid forms of venetoclax and processes for the preparation of venetoclax
IL270909A (en) Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor
EP3710009A4 (en) Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
IL250280B (en) Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds, derivatives thereof and pharmaceutical compositions comprising them
EP3258962A4 (en) Mixed allergen compositions and methods for using the same
EP3546460A4 (en) Pyrimido[5,4-b]indolizine or pyrimido[5,4-b]pyrrolizine compound, preparation method and use thereof
HK1247203A1 (en) Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
IL262257B (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
EP3440719A4 (en) Interconnect capping process for integration of mram devices and the resulting structures
HK1256044A1 (en) Pyrido[1,2-a]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor
EP3120994A4 (en) Hollow structural body and component for vehicles
PT3135110T (en) 1,7-diaryl-1,6-heptadien-3,5-dion derivatives, methods of making and using the same
IL251107B (en) Derivatives of-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one, pharmaceutical composition comprising them and their use in treating cns sisorderes.
GB201802644D0 (en) Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
SG11202001266XA (en) Process for the preparation of low haze and color stable styrenic polymers
IL253427B (en) Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis
HK1257427A1 (en) A process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one
PL3710445T3 (en) Process for the preparation of raltegravir
HUE057706T2 (en) Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof
EP3294252A4 (en) Massager for body cavities and methods for using the same
EP3302784A4 (en) Adsorbent bioprocessing clarification agents and methods of making and using the same